AARD vs MQT Comparison

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a diversified, closed-end investment management company. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S federal income taxes. The majority of its managed assets are invested in municipal bonds exempt from U.S. federal income taxes. The fund invests in municipal bonds that are in the three highest quality rating categories, or are deemed to be of comparable quality by the investment adviser at the time of investment. These are mainly long-term municipal bonds with maturities of more than ten years at the time of investment, having exposure to different sectors. The fund can also invest directly in such securities or synthetically through the use of derivatives.